Finally, on July 24, 2024, Sage Therapeutics disclosed that a Phase 2 study of SAGE-324 as a treatment for ET "did not demonstrate a statistically significant dose-response relationship in change from ...
The phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal.
The dodo is one of 13 species with whom visitors can chat thanks to artificial intelligence. A pilot scheme will see every school in Liverpool offered the chance to use a pioneering platform.